{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-012901","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.760391+00:00","generated_at":"2026-06-26T09:45:44.387510+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones","bullets":["Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.","AltheaDx had <$1M revenue in 2021; its IDgenetix test focuses on mental health pharmacogenomics.","Expected Q2 2022 close; subject to AltheaDx stockholder approval and other customary conditions.","CEO Derek Maetzold and Chairman Daniel Bradbury are AltheaDx directors and beneficial owners, creating related-party transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-012901","json":"https://secwatch.observer/filing/0001140361-22-012901.json","markdown":"https://secwatch.observer/filing/0001140361-22-012901.md","text":"https://secwatch.observer/filing/0001140361-22-012901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000114036122012901/0001140361-22-012901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000114036122012901/ny20003735x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:45:44.387510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}